Video: Anti-Idiotypic antibodies for development of CAR T cell therapies

Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis.

In this interview at the 11th EBF Open Symposium, Michael Schwenkert, Technical Sales Manager, Custom Antibodies, describes the challenges for the development of CAR T cell therapies that can be addressed using anti-idiotypic antibodies. He discusses how Bio-Rad generates custom antibodies for this purpose and for bioanalytical pharmacokinetic and immunogenicity assays.